US FDA releases 2013 guidance plans for pharma; social media guide absent yet again
This article was originally published in SRA
Executive Summary
The US Food and Drug Administration's drugs unit has posted on the agency's website a list of new or revised guidances it expects to publish this year, including one describing its expectations for submitting clinical pharmacology data to back up the biosimilarity of investigational follow-on biologics1.